RESEARCH PROJECTS

Our Current Focus

hbv1.png

Characterize and further develop the liver organoid model for mechanistic studies and drug screening; HBV infected and HCC Patient-derived liver organoids and tumoroids: a personalized medicine platform. We establish 3D human liver organoid platform which supports complete viral replication upon ex vivo infection. de Crignis, E et. al., eLife, 2021; Clark et al., Cell Death Dis, 2021.

hbv2.png
  • Platform for anti-HBV drug screening and drug-induced toxicity: HBV producing organoids provide an ideal platform for drug screening allowing us to test candidate compounds for their ability to abrogate HBV replication. Importantly, we have recently shown that human liver organoids provide an important preclinical model system for drug –induced toxicity, one that cannot be filled by cells lines or animal models.

hbv3.png

  • Unbiased and candidate approach:

    • Study host and viral specific factors modulating HBV replication and viral production

hbv4.png

We have been able to establish organoid cultures from explanted HBV infected livers of patients undergoing liver transplantation and from biopsies obtained from HBV-infected but cleared functional livers eligible for liver transplantation. Rao et al, Cancer Letters, 2021.

  • Unbiased and candidate approach:

    • Identify early aberrant gene regulatory networks, biomarkers that drive HBV-mediated HCC

    •  Identification of genomic variants

 
thumbnail_IMG_1647_edited.jpg

TECHNICAL EXPERTISE

PATIENT-DERIVED LIVER ORGANOIDS

We generate liver organoids from explant of HBV infected patients.

HEPATITIS B VIRUS INFECTION

We successfully infect liver organoids derived from healthy donors in vitro.

DRUG SCREENING PLATFORM

  

CONFOCAL MICROSCOPY